Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | MMP13 | P45452 | 8/20 | 0.67 |
| ▸ | MMP2 | P08253 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | MMP14 | P50281 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5917481 | 0.88 | ALOX15 (0.70) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL85706 | 0.85 | RAB9A (1.00) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL30994860 | 0.85 | RAB9A (1.00) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL68923 | 0.84 | HRH3 (0.84) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL829242 | 0.84 | KDM4E (0.76) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL829213 | 0.84 | KDM4E (0.76) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL27383792 | 0.83 | XDH (0.59) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL333895 | 0.82 | KDM4E (0.74) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL656018 | 0.82 | KDM4E (0.74) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL31058816 | 0.82 | KDM4E (0.74) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948454-B1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) | 2017-05-31 | — | — | EP | claimed |
| US-9447105-B2 | Triazine compounds and a process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-09-20 | — | — | US | claimed |
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-12-10 | — | — | US | claimed |
| EP-2948454-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) (IN) | 2015-12-02 | — | — | EP | claimed |
| WO-2014115171-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-07-31 | — | — | WO | claimed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | claimed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | claimed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | claimed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| EP-2948454-B1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) | 2017-05-31 | — | — | EP | disclosed |
| US-9447105-B2 | Triazine compounds and a process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-09-20 | — | — | US | disclosed |
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-12-10 | — | — | US | disclosed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534695-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| WO-2004014851-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128783-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | KDM4E 1265/4885ALDH1A1 2298/4885HPGD 3749/4885 |
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | TPH2, IDO2, INMT | KDM4E 862/4885ALDH1A1 2885/4885HPGD 2149/4885 |
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | KDM4E 2180/4885ALDH1A1 4426/4885HPGD 3373/4885 |
| US-20080008708-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | KDM4E 1265/4885ALDH1A1 2298/4885HPGD 3749/4885 |
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | KDM4E 2126/4885ALDH1A1 1203/4885HPGD 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.